Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aeglea BioTherapeutics stock | 8.15

Own Aeglea BioTherapeutics stock in just a few minutes.


Fact checked

Aeglea BioTherapeutics, Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 83 staff and has a market cap (total outstanding shares value) of USD$357.2 million.

How to buy shares in Aeglea BioTherapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aeglea BioTherapeutics. Find the stock by name or ticker symbol: AGLE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aeglea BioTherapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$8.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aeglea BioTherapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aeglea BioTherapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Aeglea BioTherapeutics's share price?

Since the stock market crash in March caused by coronavirus, Aeglea BioTherapeutics's share price has had significant positive movement.

Its last market close was USD$8.15, which is 3.44% up on its pre-crash value of USD$7.87 and 132.86% up on the lowest point reached during the March crash when the shares fell as low as USD$3.5.

If you had bought USD$1,000 worth of Aeglea BioTherapeutics shares at the start of February 2020, those shares would have been worth USD$557.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,089.57.

Aeglea BioTherapeutics share price

Use our graph to track the performance of AGLE stocks over time.

Aeglea BioTherapeutics shares at a glance

Information last updated 2020-10-14.
Latest market close USD$8.15
52-week range USD$3.5 - USD$11.38
50-day moving average USD$7.3201
200-day moving average USD$7.4781
Wall St. target price USD$16.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.299

Buy Aeglea BioTherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aeglea BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeglea BioTherapeutics price performance over time

Historical closes compared with the close of $8.15 from 2020-10-19

1 week (2020-11-24) -6.75%
1 month (2020-10-30) 6.12%
3 months (2020-09-01) 10.73%
6 months (2020-06-01) -8.73%
1 year (2019-11-29) -4.68%
2 years (2018-11-30) -3.21%
3 years (2017-12-01) 72.30%
5 years (2015-11-27) N/A

Aeglea BioTherapeutics financials

Gross profit TTM USD$-64,600,000
Return on assets TTM -36.43%
Return on equity TTM -66.08%
Profit margin 0%
Book value $3.414
Market capitalisation USD$357.2 million

TTM: trailing 12 months

Shorting Aeglea BioTherapeutics shares

There are currently 2.8 million Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 6.3% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.

Aeglea BioTherapeutics's "short interest ratio" (SIR)

Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 284236). Aeglea BioTherapeutics's SIR currently stands at 10. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 10000 shares are currently held short.

However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 60 shares are currently held short) or 0.0683% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 68 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aeglea BioTherapeutics.

Find out more about how you can short Aeglea BioTherapeutics stock.

Aeglea BioTherapeutics share dividends

We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months.

Aeglea BioTherapeutics share price volatility

Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $3.5 up to $11.38. A popular way to gauge a stock's volatility is its "beta".

AGLE.US volatility(beta: 1.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.8153. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aeglea BioTherapeutics overview

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site